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Background: Ovarian cancer constitutes nearly 4% of all cancers among women and is the leading cause of death
from gynecologic malignancies in the Western world. Standard first line adjuvant chemotherapy treatments include
Paclitaxel (Taxol) and platinum-based agents. Taxol, epothilone B (EpoB) and discodermolide belong to a family of
anti-neoplastic agents that specifically interferes with microtubules and arrests cells in the G2/M phase of the cell
cycle. Despite initial success with chemotherapy treatment, many patients relapse due to chemotherapy resistance.
In vitro establishment of primary ovarian cancer cells provides a powerful tool for better understanding the
mechanisms of ovarian cancer resistance. We describe the generation and characterization of primary ovarian
cancer cells derived from ascites fluids of patients with epithelial ovarian cancer.
Methods: Chemosensitivity of these cell lines to Taxol, EpoB and discodermolide was tested, and cell cycle analysis
was compared to that of immortalized ovarian cancer cell lines SKOV3 and Hey. The relationship between drug
resistance and αβ-tubulin and p53 status was also investigated.
Results: All newly generated primary cancer cells were highly sensitive to the drugs. αβ-tubulin mutation was not
found in any primary cell lines tested. However, one cell line that harbors p53 mutation at residue 72 (Arg to Pro)
exhibits altered cell cycle profile in response to all drug treatments. Immortalized ovarian cancer cells respond
differently to EpoB treatment when compared to primary ovarian cancer cells, and p53 polymorphism suggests
clinical significance in the anti-tumor response in patients.
Conclusions: The isolation and characterization of primary ovarian cancer cells from ovarian cancer patients’
specimens contribute to further understanding the nature of drug resistance to microtubule interacting agents
(MIAs) currently used in clinical settings.
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Ovarian cancer constitutes the fifth most common
cause of cancer deaths among women in the Western
world and is the leading cause of death from gyneco-
logic malignancies. Standard first line adjuvant chemo-
therapy treatments include Paclitaxel (Taxol) and
platinum-based agents. Taxol, epothilone B (EpoB) and
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distribution, and reproduction in any mediumagents that stabilizes microtubules and arrests cells in
the G2/M phase of the cell cycle. Despite initial success
with chemotherapy treatment, many ovarian cancer pa-
tients will relapse due to chemotherapy resistance. Con-
sequently, there is a strong impetus to investigate the
molecular and biological characteristics of ovarian can-
cer to develop more effective diagnostic and therapeutic
strategies.
To date, established immortalized ovarian cancer cell
lines have served as a useful substrate to study this dis-
ease. However, immortalized tumor cell lines undergo
many manipulations during their development that may
limit our ability to translate experimental results from
cell lines to actual ovarian disease in the clinical settingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in vitro provides a powerful tool for better understand-
ing the mechanisms of ovarian cancer resistance. Ma-
lignant epithelial tumors account for about 85% of
ovarian cancers. Ascites is commonly present in women
with epithelial ovarian cancer, and it is associated
with advanced-stage disease. Paracentesis is usually
performed to alleviate pain and discomforts, and it may
collect 2–4 liters of ascites fluid. We describe here a
modified protocol to isolate and grow in vitro cultures
of primary ovarian cancer cells derived from ascites
fluids of patients with histologically confirmed epithelial
ovarian cancer. Tumor cells can be easily isolated from
ascites and they may survive for days or months either
dividing or not dividing before eventually dying, or may
divide repeatedly requiring sub-culturing or splitting.
We have established a series of primary ovarian cancer
cell cultures from the ascites of patients with ovarian
carcinoma and have characterized them while still at an
early stage in culture. We have studied their growth
characteristics, histochemical properties, and used them
as a model to study in vitro sensitivity to microtubule
interacting agents. In particular, we have studied cell
cycle analyses of primary ovarian cancer cells treated
with Taxol, EpoB and discodermolide, and compared it
to that of immortalized ovarian cancer cell lines SKOV3
and Hey - commonly used for ovarian cancer studies.
Although it has been widely reported that Taxol exerts
cytotoxic effects to primary ovarian cancer cells [5], this
is the first time to the best of our knowledge, that the
sensitivity to EpoB and discodermolide is described.
Human malignant tumors are characterized by abnor-
mal proliferation resulting from alterations in cell
cycle-regulatory mechanisms. The regulatory pathways
controlling cell cycle phases include several oncogenes
and tumor suppressor genes that display a range of
abnormalities with potential usefulness as markers of
evolution or treatment response in ovarian cancer. It is
known that MIAs alter cytoskeleton equilibrium in
tumor cells and consequently affect cell proliferation
and drug resistance. Therefore, tubulin sequence in the
newly generated primary tumor cells has been assessed
in this study. Most importantly, because p53 tumor sup-
pressor protein plays a major role in modulating cellular
response to therapeutic agents and it is implicated in
the late stage of malignant transformation, p53 mutants’
analysis has been evaluated in ascites-derived primary
tumor cells.
Our data demonstrate that the primary ovarian cancer
cells we have developed provide a direct tool for the
study of fresh primary tumor cells derived from patients
with ovarian cancer allowing further characterization of
the disease through ex vivo chemosensitivity assays and
gene profiling.Results
Establishment of ovarian cancer cell cultures from
patients’ ascites
Peritoneal ascites specimens were collected at the time
of surgery from 25 patients with histologically confirmed
epithelial ovarian cancer. All patients were scheduled to
undergo laparatomy for diagnostic and/or therapeutic
purposes or clinically indicated paracentesis. Primary
ovarian cancer cells were isolated from approximately
250 ml of patients’ ascites fluid and cultured with growth
media as reported in Material and Methods. Ovarian
cells were found as single cells or small grape-like clus-
ters in the ascites fluids – this would conveniently avoid
the need for mechanical or enzymatic desegregation.
This report describes the isolation and characterization
of primary ovarian cancer cells from five different
patients (SS2 to SS6). After six days of in vitro culture
(Figure 1A) primary cells appear as confluent monolayer
illustrating typical epithelial cobblestone morphology.
To confirm the epithelial origin, immunofluorescent de-
tection staining of cytokeratin expression was performed
on all primary cells in culture (Figure 1B).
Sensitivity assay to Taxol, epothilone B and
discodermolide
To characterize the drug sensitivity profiles, the newly
established primary ovarian cancer cell cultures were
tested in cytotoxicity assays with Taxol, EpoB and disco-
dermolide. Cells developed from patients’ ascites have
been exposed to scalar concentrations of each drug. The
values reported in Table 1 show the quantitative measure
of the half maximal (50%) inhibitory concentration - IC50-
of the drugs. SS3, SS4 and SS5 displayed the highest
sensitivity to all drugs, with IC50 values ranging from 0.17-
0.19 nM for Taxol, 0.15-0.34 nM for EpoB and 1.1-1.5 for
discodermolide. IC50 values relative to immortalized ova-
rian cancer cell lines SKOV3 and Hey are also reported.
As shown in Table 1, the IC50 values vary widely among
the various cell lines when treated with Taxol, EpoB and
discodermolide. We noted that SS2 cells demonstrated
the lowest sensitivity and highest resistance to Taxol com-
pared to all other cell lines in this series. Conversely, SS6
cells demonstrated the lowest sensitivity and highest
resistance to EpoB and discodermolide compared to all
other cell lines. These variations of IC50 values among the
freshly generated primary cells lines demonstrate that pri-
mary cells lines indeed display individual profiles inherent
for sensitivity and resistance to various microtubule stabil-
izing agents (MSAs).
Cell cycle kinetics of primary ovarian cancer cells
following exposure to microtubule interacting agents
In order to better comprehend the mechanisms of diffe-







Figure 1 Primary cultures of epithelial ovarian cancer cells
isolated from five patients’ ascites fluid. (A) Confluent monolayer of
primary cells illustrating typical epithelial cobblestone morphology.
(B) Immunofluorescent detection of cytokeratin expression in primary
ovarian cancer cells demonstrating the epithelial origin. An area
representative of the entire image was selected.
Table 1 IC50 values for primary and immortalized ovarian
cancer cells upon drug treatment
Taxol Epothilone B Discodermolide
SS2 1.10 nM 0.05 nM 3.20 nM
SS3 0.19 nM 0.23 nM 1.14 nM
SS4 0.19 nM 0.15 nM 1.45 nM
SS5 0.17 nM 0.34 nM 1.18 nM
SS6 0.54 nM 2.51 nM 6.28 nM
SKOV3 10.0 nM 3.2 nM 52.1 nM
HEY 2.5 nM 0.9 nM 39.3 nM
IC50 values were determined after 72 hours (for immortalized cells SKOV3 and
HEY) and 12 days (for primary ovarian tumor cells) of incubation at 37°C with
the indicated drugs. Concentration range for primary tumor cells: Taxol and
EpoB: 0.1-50 nM, discodermolide: 0.2-100 nM; for Hey and SKOV3 cell lines:
Taxol and EpoB: 0.5-250 nM; discodermolide: 1–500 nM.
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ascites-derived ovarian cancer cell lines. Figure 2 shows
propidium iodide staining performed to evaluate the
effect of Taxol, EpoB and discodermolide on modulating
cell cycle. Ovarian cancer cells generated from patients’s
ascites were treated with scalar concentrations of the
drugs (4 to 200 nM) and cell cycle was evaluated 72 -
hours after treatment. However, because the number of
cells in each patient’s ascites varied substantially, treat-
ment with all drugs was not performed for each speci-
men. Figure 2 (left panel) shows the characterization of
the cell cycle in response to Taxol treatment. Data rela-
tive to the cell cultures SS2, SS4, SS5 and SS6 are
reported. After treatment with Taxol, an overall decrease
in cells arrested in the G0/G1 phase is observed in SS2,SS4 and SS5 specimens. Concurrently there is an increase
in cells arrested in the G2/M phase of the cell cycle. Al-
though the cellular response of these three cell specimens
is overall consistent, the extent and the time of the re-
sponse is slightly different; SS5 cells in fact require a treat-
ment with 50 nM to be arrested in the G2/M phase while
SS2 and SS4 respond to lower doses of the drug. Interest-
ingly, SS6 cells display a very different response to Taxol
treatment. SS6 cells were treated with 4, 8, 12, 25, 50, 100
and 200 nM Taxol: no modulation of the cell cycle can be
observed after 72 hrs of treatment. These data suggest that
the ascites-derived SS6 primary ovarian cancer cell speci-
men might be resistant to Taxol treatment, and cell cycle
arrest cannot be induced in this case at the drug treatment
conditions used here.
To evaluate the ability of other MSAs to interfere with
cell cycle of primary ovarian cancer cells, SS2, SS4 and
SS6 specimens were selected for treatment with EpoB and
dicodermolide. Cell cycle is modulated by treatment with
both drugs similarly to Taxol-treated cells. SS2 and SS4
specimens’ cell cycle is arrested by nanomolar concentra-
tions of EpoB and disodermolide: 10 nM and 12 nM of
EpoB induce cycle arrest at the G2/M phase of SS2 and
SS4 cells respectively (Figure 2, middle panel). A higher
dosage of 50 nM of discodermolide is necessary to induce
a similar pattern of cell cycle modulation in SS2 and SS4
cells (Figure 2, right panel). Similarly to Taxol, cell cycle of
SS6 specimen is not arrested or modified to any extent by
treatment with EpoB and discodermolide. The results also
show that DNA content in the cells derived from this
specimen does not reveal any changes in cell cycle distri-
bution following drug treatment. This finding suggests
that SS6 specimen is highly resistant to Taxol, EpoB and
discodermolide in vitro.
αβ-tubulin and p53 mutational assay
It is known that expression of mutant tubulin and p53



































































Figure 2 Characterization of cellular response to MSAs. Ascites-derived primary ovarian cancer cells were treated with Taxol, EpoB or
discodermolide at the indicated doses. Cells were analyzed for cellular proliferation and DNA content was measured by FACS analysis using
propidium iodide after 72 hrs. One representative sample of 2–3 replicates with similar results is shown.
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fically. To understand why different cell specimens ex-
hibit different sensitivity to same drugs, we isolated
RNA from the five ascites-derived ovarian cancer cells,
followed by cDNA preparation and analyzed the se-
quence of αβ-tubulin and p53. Table 2 shows that no
αβ-tubulin modification was detected in the primary
ovarian cancer cells. Sequence variations in p53 were
identified in the RNA from two specimens. Specifically,
a variant in exon 8, which confers an amino acidic sub-
stitution of arginine to proline at codon 72 was identi-
fied in SS3 and SS6 specimens. Interestingly, SS6 is also
the only ovarian cancer cell line showing resistance to
the treatment with EpoB, Taxol and discodermolide asshown in the cell cycle analyses reported in Figure 2.
This finding suggests a possible correlation between the
observed p53 mutation and cell sensitivity to the chemo-
therapeutic drugs tested in this study.
Cell cycle kinetics of immortalized cell lines after
treatment with EpoB
To further investigate the correlation of p53 status with
drug sensitivity, we compared the effects of EpoB treat-
ment on the cell cycle of two immortalized ovarian can-
cer cell lines: a p53−/− null cell line, SKOV3, versus a
p53+ wild type cell line, Hey. Figure 3 shows the cell
cycle analysis performed after 24 hrs of treatment with






















Figure 3 Effect of EpoB on p53−/− cell line (SKOV3) versus a
p53+ cell line (Hey). Cells were treated with scalar concentrations
of EpoB (4nM to 200nM) and propidium iodide staining was
performed after 24 hrs of treatment to assess cell cycle response to
the drug.







W: wild type; Arg72Pro: sequence variant in p53 exon 8, which confers an
amino acid substitution of arginine to proline at codon 72.
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cells SKOV3, while a higher dosage of 50 nM is neces-
sary to noticeably arrest cell cycle of the majority of the
p53+ cells Hey. Interestingly, when cell cycle response to
EpoB of the primary ovarian cancer cell line SS6 bearing
mutation on p53 (Figure 2B) is compared to the re-
sponse of the immortalized p53−/− null cell line SKOV3
also carrying p53 mutations (Figure 3), an opposite effect
can be observed. In fact, while SS6 primary cells are not
affected by EpoB treatment, SKOV3 cell cycle is arrested
by as low as 4 nM of the drug. Additionally, the primary
cells SS4 and the immortalized cell line Hey, despite
both carrying wild-type p53 sequences, show different
sensitivity to EpoB, as SS4 cell cycle is arrested by lower
concentrations compared to Hey cells. Altogether these
data show that primary ovarian cancer cells freshly iso-
lated from patients can be differently affected by chemo-
therapeutic drugs compared to immortalized cell lines
that are commonly used as in vitro models for human
ovarian cancers. We therefore can speculate that pri-
mary human ovarian cancer cell lines generated as we
described may provide clinically relevant models more
suitable for investigation of the in vitro biological char-
acteristics of ovarian cancers, which in turn may lead to
the discovery of new therapies for these tumors.
Discussion
In this report we describe the isolation and characterization
of primary human ovarian cancer cell lines derived from
untreated patients diagnosed with histologically confirmed
epithelial ovarian cancer. We confirmed that it is feasible to
develop primary ovarian cancer cells from patients’ ascites
fluids, and that these cells can be used to characterize
mechanisms of action of microtubule-stabilizing agents
(MSAs), Taxol, epothilone B and discodermolide. Further-
more we report that p53 and tubulin mutational analysis
can also be assessed in the newly generated primary tumor
cells.
A simple protocol has been designed to isolate single
cells and small grape-like clusters of ovarian cancer cells
found in the ascites fluids. In general, after a patient spe-
cimen was plated in vitro, the first cells to attach on the
plastic of the flask were the fibroblasts; macrophages
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could divide only a finite number of times, until the
cancer cells took over the culture. Ovarian cancer cells
grew in vitro as to acquire a monolayer distribution with
the typical epithelial cobblestone morphology (Figure 1).
Importantly, no mechanical or enzymatic disaggregation
was involved in our protocol for the establishment of
cell culture, and the least manipulation of the cells was
performed. Therefore the original properties as well as
the physical features of the tumor cells were maintained.
While most ovarian carcinoma cell lines commercially
available have been passaged for prolonged periods and
may therefore have lost certain characteristics, the cell
lines described herein were studied at early passage
numbers, and stored in liquid nitrogen to maintain a
source of cells. Despite tumor heterogeneity and un-
known source of the tumor cells found in the ascites
(primary tumor versus metastasis), these cells can be con-
sidered as a close representation of the tumors in their
natural state, and can be used for further characterization
such as genotyping, drug sensitivity assays, and establish-
ment of xenograft in vivo models. In this study, ovarian
cancer cell lines isolated as we described, provided a direct
and straightforward tool to investigate the sensitivity to
commonly used anti-neoplastic agents belonging to the
MSA family. Specifically, we evaluated cytotoxicity of
Taxol, EpoB and discodermolide by exposing primary
ovarian cancer cells to scalar concentrations of each drug.
We observed that all cell lines were affected by the treat-
ment and it was feasible to define the IC50 for each drug.
Because these cells are highly selected, their behavior may
differ significantly in regard to growth characteristics and
response to drug. Within the five cell lines reported here,
IC50 values varied upon the same drug treatment. In par-
ticular, SS2 showed the highest IC50 to Taxol and SS6
showed the highest IC50 values to EpoB and disco-
dermolide. Additionally, SS6 showed no cell cycle
modulation after treatment with Taxol, EpoB and disco-
dermolide, suggesting a mechanism of resistance in the
specimen derived from that patient.
In order to further characterize the cytotoxic response
to chemoterapuetic drugs, different doses of Taxol, EpoB
and discodermolide were tested (see Table 1). We found
that the primary cell lines we established were able to re-
spond to each drug and that cell cycle is extensively
modified by the drugs. Studies performed with immor-
talized ovarian cancer cell lines show that microtubule
interacting agents (MIAs) generally induce modification
of microtubule network and G2/M arrest in proliferating
cells. After 72-hour incubation with cytotoxic concentra-
tions of the drugs, the primary tumor cell lines we gen-
erated showed modifications of the cell shape (data not
shown). Cell cycle analysis indicated that exposure to
the drugs decreased the proportion of cells in the Sphase and increased the proportion in the G0/G1 and/or
G2/M phases. However, the dose-dependent sensitivity
to each drug may vary significantly, and SS6 cell cycle
distribution was not affected by any drugs (Figure 2).
Immortalized cell lines are commonly used in in vitro
models to study the effects of chemotherapeutic drugs
in ovarian cancer. We compared cell cycle modifications
induced by EpoB on immortalized ovarian cancer cell
lines SKOV3 and Hey to those of freshly isolated pri-
mary tumor cells. SKOV3 and Hey showed a cell cycle
pattern that is very different from that described for the
primary tumor cells isolated from patients (Figure 3).
Specifically, the primary tumor cells grew much slower
than the immortalized cells. It was observed that when
the same number of cells was plated, primary tumor
cells required approximately 10–12 days to achieve 60-
70% confluency, whereas immortalized cells only needed
3 days to reach 95% confluency. Moreover, a different
cell cycle response is observed between the two cell
lines, probably due to their different p53 status: p53−/−
(SKOV3) and p53+ (Hey). It is known that patients with
mutant p53 ovarian tumors were found more responsive
to paclitaxel-based chemotherapy [6], indicating that
p53 status might differentially affect drug response in
different cell types. The introduction of mutations in
drug-targeted proteins is one of the mechanisms affect-
ing response to anti-cancer drug treatments. Although
the molecular basis of drug sensitivity and resistance is
complex, the p53 tumor suppressor protein appears to
play a major role in modulating cellular response to
therapeutic agents. p53 tumor suppressor protein is the
most commonly mutated protein in diverse cancers and
it is implicated in the late stage of malignant transform-
ation [7]. An extensive number of studies have shown
somatic p53 mutations to be a predictor of response to
treatment in ovarian cells resistant to cisplatin [8]. Gene-
rally, the presence of wild-type p53 in tumor cells corre-
lates with a good clinical response to drug therapy.
Mutations in the p53 gene are extremely frequent in
ovarian cancer and they vary among the histological types.
Not surprisingly, loss of apoptotic functions appears to be
a major cause of resistance to cytotoxic drugs and p53
mutations are observed in more than 50% of advanced
ovarian carcinomas [9]. Presence of wild-type p53, on the
other hand, does not necessarily ensure a chemosensitive
phenotype, and a clinical study has underscored this very
convincingly reporting that, among the group of chemo-
resistant ovarian tumors, 37% had wild-type p53 and 63%
had mutant p53. The study also reports that loss of p53
function has been associated with the lack of response to
high-dose cisplatin in ovarian cancer patients [10]. To in-
vestigate the reasons for different drug response observed
in our freshly generated primary ovarian cancer cells, a
p53 mutational study was assessed and we found that two
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sense mutation at codon 72 in the exon 8 of the p53 gene.
This mutation confers an amino acidic substitution of
arginine to proline (Figure 3). The Arg72 form has a high
risk of developing into other forms of cancer compared to
the Pro72 form and it induces apoptosis markedly more
than the Pro72 variant [11]. These differences may influ-
ence cancer risk or treatment [12]. Interestingly, one of
the two cell lines carrying the codon 72 mutation showed
no cell cycle modifications after treatment with Taxol,
EpoB and discodermolide. This finding suggests that cor-
relations between the p53 mutation observed in the pri-
mary cells and their sensitivity to chemotherapeutic drugs
cytotoxicity can be speculated.
The significance of codon 72 polimorphysm in the re-
sistance to chemotherapeutic drugs and patient prognosis
is still controversial [13-15]. Although the polymorphism
is balanced, it varies with latitude and race, and is main-
tained at different allelic frequencies across the population
[16], it is suggested to result in a drastically altered
biological and biochemical behavior of p53 in vitro. Its
clinical relevance is correlated to differences in apoptosis
susceptibility to cytotoxic drugs and the response and
survival to radiochemotherapy [13,17,18]. Codon 72 muta-
tions have been associated with urothelial [19], thyroid
[20], colorectal carcinomas [21] and chronic myeloid
leukemia [22], whereas homozygosity for arginine 72 was
associated with advanced lung cancer [23]. In Italian
breast cancer patients, the retention of an arginine allele
was correlated with a reduction of survival in one study
[24]. Furthermore, p53 protein encoded by the arginine
allele appears to be more susceptible to HPV-E6 protein-
induced degradation [25]. p53 polymorphism can partially
explain the heterogeneity of cell cycle response observed
in our primary cell lines after drug treatment. We hypo-
thesize that: (i) different p53 mutants may have specific
properties against different chemotherapeutic drugs, as
the expression of a specific p53 mutant results in resis-
tance to one drug but does not affect the sensitivity
against another drug; (ii) although the codon 72 mutants
tend to confer resistance to anticancer drugs, it is not an
universal phenomenon and depends on the mutation and
drug used; (iii) cell type–specific effects of the codon 72
mutants may be observed. Our data generated from ana-
lysis of drug response in primary tumor cells, in addition
to the data published from others, highlight the signifi-
cance of evaluating the role of p53 mutations in conjunc-
tion with the polymorphic status before the therapeutic
regimen is decided upon.
Because MSA alter cytoskeleton equilibrium in tumor
cells and, because abnormal microtubule dynamics im-
pair mitotic spindle function and inhibit normal cell pro-
liferation [5,26-29], the relationship between MSAs and
drug resistance in our primary ovarian cancer cells hasalso been evaluated. Factors that influence microtubule
dynamics include tubulin mutations that affect interac-
tions between protofilaments or binding of regulatory
proteins of different phosphorylation states. These tubu-
lin mutations could result in microtubules with increased
dynamics or decreased stability [30,31]. It has been sug-
gested that an alteration in microtubule dynamics may be
involved in Taxol or EpoB resistance/dependence pheno-
type [28,32]. Specifically, mutations in β-tubulin have been
found in a variety of Taxol and EpoB resistant cells [33],
where they are responsible for microtubule stability de-
crease. Some of these resistant cells may become more
sensitive to microtubule-destabilizing drugs, such as vin-
blastine and colchicine [26,34]. In the light of these obser-
vations, we tested αβ-tubulin sequence in the five primary
ovarian cancer cell lines described herein (Table 2). No
αβ-tubulin sequence mutations were found, however it
remains to be assessed whether different tubulin mutants
exist and to what extent these variants affect drug resist-
ance. In addition, MSAs may alter the expression and
phosphorylation of microtubule associated proteins that
may influence the dynamic stability of microtubules.
Although p53 and tubulin mutants may explain the
heterogeneity observed in the response of primary ovar-
ian cancer cells to the chemotherapeutic drugs used in
this study, several additional biological reasons can be
hypothesized. The majority of our data indicated that ex-
posure to the drugs arrested cell cycle of primary tumor
cells on the G2/M phases, although a clear heterogeneity
in the cell cycle patterns among the different specimens
can be observed. Generally, increased cytotoxicity was
reported with higher drug concentrations, yet a different
dose–response relationship was observed for each cell
line and each individual drug. It would be interesting to
assess whether the dose–response patterns vary for com-
bined drug exposures and if the combination is more ac-
tive than each individual drug. The protocol we have
generated for isolation of tumor cells form ascites fluids
does not distinguish from primary tumor and its metas-
tases in the same patient. This may lead to different
sensitivity profiles to the same drug or to different drugs
as well. Tumor heterogeneity, therefore, reduces the reli-
ability of the test in making clinical decisions.
The differences in cell cycle response to EpoB observed
in primary tumor cells relatively to immortalized cell lines
Hey and SKOV3, can be attributed to the cross-talk
between the tumor microenvironment and malignant
epithelial cells, that can largely influence apoptotic re-
sponse. Primary cells isolated from patients’ ascites have
been recently in contact with tumor microenvironment
and received specific signals that immortalized cells cul-
tured in vitro for longer time, may have lost. Additionally,
it appeared from our studies and studies from others that,
even in supposedly morphologically homogeneous cell
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displaying different patterns of response to similar cyto-
toxic agents may be identified. In this scenario it is likely
that neither the response to a single drug nor to drug
combinations could be predicted for a particular tumor
specimen other than by direct testing. This underscores
the need to characterize an individual patient’s chemo-
sensitivity profile before drug treatment. Advances in cell
culture methodologies have made it possible to establish a
variety of human carcinoma cell lines from surgical tissues
and biopsy specimens. Therefore, despite tumor hetero-
geneity and uncertain origin of ascites tumor cells, the
isolation and establishment of primary tumor cells derived
from patients and the analyses of their response to various
chemotherapeutic drugs would be a most useful tool in
making clinical decisions.
Conclusions
To overcome drug resistance in patients, we need methods
that reliably measure individual tumor sensitivities. The re-
sults described in this work show that we have generated a
simple protocol to isolate and establish primary ovarian
cancer cells from ascites fluids. We demonstrated that
these primary ovarian cancer cells can be used for in vitro
studies to provide information on the effect of microtubule
interacting-agents such as Taxol, EpoB and discodermolide
in vitro thus delineating whether a pattern of resistance
exists. Furthermore we report that p53 and tubulin muta-
tional analysis can also be assessed in the freshly generated
primary tumor cells. These primary tumor cells can be
used for a variety of additional studies including geno-
typing and establishment of xenograft in vivo models, and
specifically we have shown and discussed the relevance
they may play in understanding the biology of resistance to
chemotherapeutic drugs.
Methods
Isolation of primary ovarian cancer cells from ascites
With Institutional Review Board approval, physicians in the
division of gynecologic oncology at Montefiore Medical
Center obtained ascites specimens from 25 patients with
ovarian cancer at the time of surgery. Institutional informed
patient consent was obtained for this study. Patients were
scheduled to undergo laparatomy for diagnostic and/or
therapeutic purposes or clinical indicated paracentesis.
Approximately 250 ml of ascites was obtained from each
patient. In each cell culture flask 20 ml of fresh ascites fluid
was mixed with 20 ml of growth medium RPMI1640
media, supplemented with 10% FBS, 100 unites/ml penicil-
lin and 100 μg/ml streptomycin. Regular passaging of the
cell lines was carried out in complete culture medium con-
ditioned with 20% of their own medium and 10% of autolo-
gous filtered ascites. After 4–5 passages, the cell cultures
were completely free of fibroblasts and mesothelial cells.Aliquots of cells were frozen in liquid nitrogen, at different
passage numbers, in 5% dimethyl sulfoxide (DMSO) in
FCS. Cells were used for phenotypic characterization and
drug resistance analyses after three days of culture (passage
1–2) and were fully confluent after six days of culture. Cells
were isolated from all 25 patients in the study cohort, and
subsequently cultured and frozen in liquid nitrogen for fu-
ture studies. Six out of the 25 patient specimens were se-
lected for the microtubule agents studies described here.Immortalized cell lines and microtubule interacting agents
The human ovarian cancer cell lines SKOV3 and Hey
were grown at 37°C in RPMI 1640 containing 10% FBS.
Taxol, EpoB and discodermolide were obtained as previ-
ously reported [26,35].Immunofluorescence analysis of tumor cell epithelial origin
Primary cells isolated from ascites fluid were analyzed to
assess epithelial origin. A total of 1 × 106 cells were
washed with PBS and non-specific binding was blocked
with 5% BSA in PBS for 1 h at 37°C. Cells were washed
with PBS and incubated for 20 minutes on ice in the
dark with anti-cytokeratin mAb, followed by incubation
with FITC-labeled secondary anti-mouse antibody. The
cells were washed with PBS with 2% fetal calf serum
(Sigma-Aldrich, St. Louis, MO) and cytospun into glass
slides and analyzed with a microscope.Cytotoxicity assay
A methylene blue-based cytotoxicity assay was devel-
oped from previous research to study the drug resistance
profiles of the primary ovarian cancer cells [36,37]. Ap-
proximately 5,000 cells were seeded into each well in a
96-well plate and allowed to settle for 16 h, and drugs
were added to the first well of the plate and serial di-
luted to subsequent wells. After 72 hrs of incubation for
Hey and SKOV3 cells and 12 days for primary tumor
cells, the medium was discarded, and 100 μl of a methy-
lene blue solution (0.5% in ethanol:water; 50%, v/v) were
added to each well. One hour later, unbound methylene
blue was washed off with water and bound stain was
solubilized by the addition of 1 ml of 1% SDS solution.
The plates were stirred gently on a rotator for 1 h at
room temperature, and the absorbance in each suspen-
sion was read at 630 nm in a spectrophotometer. The
staining in the control well was taken as 100%, and
the IC50 were defined as the drug concentrations that
inhibited the cell growth by 50%. Drug concentration
range for primary tumor cells: Taxol and EpoB: 0.1-50
nM, discodermolide: 0.2-100 nM; for Hey and SKOV3
cell lines: Taxol and EpoB: 0.5-250 nM; discodermolide:
1–500 nM.
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After treatment with Taxol, EpoB and discodermolide,
cells were collected by centrifugation and washed twice
with ice-cold PBS. Cells were resuspended and fixed in
70% ethanol at 4°C for 1 h. After centrifugation, cells were
washed twice in PBS and resuspended in 1 ml of PBS
containing 20 μg/ml of propidium iodide and 5 Kunitz
units of DNase-free RNase A. Samples were incubated at
37°C for 30 min and the cell cycle distrubution was deter-
mined by flow cytometry using a FACSCalibur (Becton-
Dickinson, Franklin Lakes, NJ). Two to three replicates
were performed for each sample.
Tubulin and p53 sequence analysis
Total RNA was prepared from cells as described [38] and
reverse transcribed to cDNA. For RT-PCR and sequencing
four overlapping sets of primers were designed based on
the published sequence (GenBank accession no. AF070561)
and previously published primer sequences [34]. Total
RNA was isolated using Total RNA isolation reagent
(ABgene, Rochester, NY) and contaminating DNA removed
with RNase-free DNase I treatment (Boehringer Mann-
heim, Indianapolis, IN) for 30 min at 37°C. Total RNA
(1 μg) was reverse transcribed and the cDNA used for RT-
PCR. PCR-amplified products were purified using the
QIAquick gel extraction kit (Qiagen, Valencia, CA). The
amount of cDNA was quantified, and ∼200 ng of cDNA,
with 6 pmol of either primer, forward or reverse, was
sequenced using an automated DNA sequencing system
(ABI Prism). The accession numbers are as follows: TP53,
AAD28535; Tubulin alpha chain, Q71U36; Tubulin beta
chain, Q13509.
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